Skanska to build for pharmaceutical company in New Jersey for USD 60.5 M, about SEK 410 M


Skanska to build for pharmaceutical company in New Jersey for USD 60.5 M, about
SEK 410 M

Skanska has been chosen as construction manager for expansion of a
pharmaceutical facility in New Jersey. The contract amount totals USD 60.5 M, or
approximately SEK 410 M, which will be included in order bookings for the fourth
quarter. The customer is one of Skanska's repeat customers within the
pharmaceutical industry.

The project involves construction of a three-story, approximately
9.300-square-meter building and renovation of an existing 11,600-square-meter
building. Among other objectives, the project will improve and expand the
company's supply operations and logistics management. 

This is the fifth project that Skanska is performing at the facility since 2005.
Previous projects include office and laboratory renovations, a new parking deck,
cafeteria and fitness center as well as a new clinical manufacturing structure. 

Skanska USA Building is a leading U.S. provider of construction, general
contracting, design  and design-build services. The company also provides
pharmaceutical validation services to clients. Customers represent a broad
spectrum of American industries, including the pharmaceutical, healthcare,
educational, electronics, infrastructure, sports and entertainment industries.
The company is based in Parsippany, New Jersey and has approximately 3,900
employees. Revenues totaled approximately SEK 30 billion in 2006.

In addition to a number of biotechnology facilities throughout the U.S. and
Puerto Rico, Skanska USA Building is currently constructing the New Meadowlands
Stadium and managing an extensive renovation of UN Headquarters in New York
City.

For further information please contact:

Tom Crane, Senior Vice President Communication, 
Skanska USA Building, tel +1 973 753 3450 
Peter Gimbe, Press Officer, Skanska AB, tel +46 8 753 88 38
Direct line for the media: +46 8 753 88 99


This and previous releases can also be found at www.skanska.com

Skanska AB may be required to disclose the information provided herein pursuant
to the Securities Markets Act.

Skanska is one of the world's leading construction groups with expertise in
construction, development of commercial and residential projects and
public-private partnerships. The Group currently has 56,000 employees in
selected home markets in Europe, in the US and Latin America. Headquartered in
Stockholm, Sweden and listed on the Stockholm Stock Exchange, Skanska's sales in
2006 totaled SEK 126 billion.

Attachments

11122019.pdf